Tazeen Ahmad
Stock Analyst at B of A Securities
(3.26)
# 1,152
Out of 4,412 analysts
123
Total ratings
45.61%
Success rate
1.44%
Average return
Main Sectors:
38 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Downgrades: Underperform | $24 → $14 | $13.69 | +2.26% | 12 | Apr 17, 2024 | |
| INZY Inozyme Pharma | Maintains: Buy | $16 → $14 | $4.44 | +215.32% | 2 | Apr 9, 2024 | |
| ANNX Annexon | Maintains: Buy | $7 → $10 | $4.70 | +112.77% | 4 | Mar 28, 2024 | |
| FATE Fate Therapeutics | Maintains: Underperform | $2 → $6 | $3.80 | +57.89% | 2 | Mar 28, 2024 | |
| INCY Incyte | Maintains: Neutral | $69 → $67 | $51.68 | +29.64% | 2 | Mar 13, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $33 → $30 | $16.71 | +79.53% | 8 | Mar 12, 2024 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $15 | $4.75 | +216.12% | 1 | Feb 9, 2024 | |
| PRTA Prothena Corporation | Downgrades: Neutral | $68 → $38 | $20.87 | +82.08% | 2 | Jan 30, 2024 | |
| ACHL Achilles Therapeutics | Downgrades: Underperform | $7 → $0.5 | $0.76 | -34.21% | 1 | Dec 14, 2023 | |
| PHVS Pharvaris | Maintains: Underperform | $8 → $11 | $23.35 | -52.89% | 2 | Dec 7, 2023 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $52 → $85 | $49.86 | +70.48% | 1 | Dec 5, 2023 | |
| PTCT PTC Therapeutics | Maintains: Underperform | $43 → $23 | $28.57 | -19.50% | 9 | Sep 19, 2023 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Neutral | $36 → $31 | $42.47 | -27.01% | 2 | Aug 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Upgrades: Buy | $22 → $27 | $38.28 | -29.47% | 5 | Aug 2, 2023 | |
| BCRX BioCryst Pharmaceuticals | Upgrades: Buy | $10 | $4.16 | +140.38% | 2 | Jul 13, 2023 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $28 → $33 | $23.25 | +41.94% | 2 | Jun 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $164 → $176 | $128.77 | +36.68% | 20 | May 15, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Underperform | $7 → $2 | $4.34 | -53.92% | 2 | Apr 24, 2023 | |
| ASND Ascendis Pharma | Maintains: Buy | $132 → $92 | $135.90 | -32.30% | 5 | Apr 4, 2023 | |
| BNTX BioNTech SE | Maintains: Buy | $239 → $194 | $87.21 | +122.45% | 5 | Mar 28, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $16 → $17 | $10.28 | +65.37% | 1 | Mar 28, 2023 | |
| GRTX Galera Therapeutics | Upgrades: Buy | $2 → $7 | $0.19 | +3,661.42% | 2 | Feb 16, 2023 | |
| PRLD Prelude Therapeutics | Downgrades: Underperform | $6 | $4.07 | +47.42% | 4 | Nov 21, 2022 | |
| SRZN Surrozen | Downgrades: Underperform | $75 → $15 | $8.98 | +67.04% | 3 | Nov 17, 2022 | |
| PRAX Praxis Precision Medicines | Downgrades: Neutral | $390 → $60 | $54.80 | +9.49% | 2 | Jun 7, 2022 | |
| PEPG PepGen | Initiates: Buy | $16 | $11.93 | +34.12% | 1 | May 31, 2022 | |
| MTEM Molecular Templates | Downgrades: Underperform | $23 | $1.71 | +1,219.65% | 1 | May 27, 2022 | |
| PYXS Pyxis Oncology | Initiates: Neutral | n/a | $4.30 | - | 1 | Nov 2, 2021 | |
| ARVN Arvinas | Initiates: Buy | n/a | $32.37 | - | 1 | Sep 9, 2021 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Buy | n/a | $44.24 | - | 3 | Jun 29, 2021 | |
| ARGX argenx SE | Maintains: Buy | n/a | $372.80 | - | 2 | Oct 6, 2020 | |
| ETNB 89bio | Upgrades: Buy | n/a | $8.26 | - | 1 | Sep 25, 2020 | |
| FULC Fulcrum Therapeutics | Downgrades: Underperform | n/a | $7.14 | - | 2 | Aug 12, 2020 | |
| DBVT DBV Technologies | Maintains: Buy | n/a | $0.68 | - | 1 | Nov 2, 2018 | |
| SPRO Spero Therapeutics | Downgrades: Underperform | n/a | $1.46 | - | 2 | Oct 16, 2018 | |
| PCRX Pacira BioSciences | Maintains: Neutral | n/a | $26.33 | - | 3 | Oct 10, 2018 | |
| PTC PTC Inc. | Maintains: Neutral | n/a | $180.99 | - | 3 | Jun 19, 2018 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | n/a | $135.99 | - | 1 | May 1, 2018 |
Sage Therapeutics
Apr 17, 2024
Downgrades: Underperform
Price Target: $24 → $14
Current: $13.69
Upside: +2.26%
Inozyme Pharma
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $4.44
Upside: +215.32%
Annexon
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.70
Upside: +112.77%
Fate Therapeutics
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $3.80
Upside: +57.89%
Incyte
Mar 13, 2024
Maintains: Neutral
Price Target: $69 → $67
Current: $51.68
Upside: +29.64%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Neutral
Price Target: $33 → $30
Current: $16.71
Upside: +79.53%
Ocular Therapeutix
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $4.75
Upside: +216.12%
Prothena Corporation
Jan 30, 2024
Downgrades: Neutral
Price Target: $68 → $38
Current: $20.87
Upside: +82.08%
Achilles Therapeutics
Dec 14, 2023
Downgrades: Underperform
Price Target: $7 → $0.5
Current: $0.76
Upside: -34.21%
Pharvaris
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $23.35
Upside: -52.89%
Apellis Pharmaceuticals
Dec 5, 2023
Upgrades: Buy
Price Target: $52 → $85
Current: $49.86
Upside: +70.48%
PTC Therapeutics
Sep 19, 2023
Maintains: Underperform
Price Target: $43 → $23
Current: $28.57
Upside: -19.50%
Cerevel Therapeutics Holdings
Aug 3, 2023
Downgrades: Neutral
Price Target: $36 → $31
Current: $42.47
Upside: -27.01%
Rhythm Pharmaceuticals
Aug 2, 2023
Upgrades: Buy
Price Target: $22 → $27
Current: $38.28
Upside: -29.47%
BioCryst Pharmaceuticals
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $4.16
Upside: +140.38%
4D Molecular Therapeutics
Jun 8, 2023
Maintains: Buy
Price Target: $28 → $33
Current: $23.25
Upside: +41.94%
Sarepta Therapeutics
May 15, 2023
Maintains: Buy
Price Target: $164 → $176
Current: $128.77
Upside: +36.68%
ADC Therapeutics
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $4.34
Upside: -53.92%
Ascendis Pharma
Apr 4, 2023
Maintains: Buy
Price Target: $132 → $92
Current: $135.90
Upside: -32.30%
BioNTech SE
Mar 28, 2023
Maintains: Buy
Price Target: $239 → $194
Current: $87.21
Upside: +122.45%
Amicus Therapeutics
Mar 28, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $10.28
Upside: +65.37%
Galera Therapeutics
Feb 16, 2023
Upgrades: Buy
Price Target: $2 → $7
Current: $0.19
Upside: +3,661.42%
Prelude Therapeutics
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $4.07
Upside: +47.42%
Surrozen
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $8.98
Upside: +67.04%
Praxis Precision Medicines
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $54.80
Upside: +9.49%
PepGen
May 31, 2022
Initiates: Buy
Price Target: $16
Current: $11.93
Upside: +34.12%
Molecular Templates
May 27, 2022
Downgrades: Underperform
Price Target: $23
Current: $1.71
Upside: +1,219.65%
Pyxis Oncology
Nov 2, 2021
Initiates: Neutral
Price Target: n/a
Current: $4.30
Upside: -
Arvinas
Sep 9, 2021
Initiates: Buy
Price Target: n/a
Current: $32.37
Upside: -
Ultragenyx Pharmaceutical
Jun 29, 2021
Upgrades: Buy
Price Target: n/a
Current: $44.24
Upside: -
argenx SE
Oct 6, 2020
Maintains: Buy
Price Target: n/a
Current: $372.80
Upside: -
89bio
Sep 25, 2020
Upgrades: Buy
Price Target: n/a
Current: $8.26
Upside: -
Fulcrum Therapeutics
Aug 12, 2020
Downgrades: Underperform
Price Target: n/a
Current: $7.14
Upside: -
DBV Technologies
Nov 2, 2018
Maintains: Buy
Price Target: n/a
Current: $0.68
Upside: -
Spero Therapeutics
Oct 16, 2018
Downgrades: Underperform
Price Target: n/a
Current: $1.46
Upside: -
Pacira BioSciences
Oct 10, 2018
Maintains: Neutral
Price Target: n/a
Current: $26.33
Upside: -
PTC Inc.
Jun 19, 2018
Maintains: Neutral
Price Target: n/a
Current: $180.99
Upside: -
Neurocrine Biosciences
May 1, 2018
Maintains: Buy
Price Target: n/a
Current: $135.99
Upside: -